Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme Ball

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Pharmacoeconomics|July 17, 2022
The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in CanadaChristopher Hillis, Colin Vicente, Graeme Ball
Pharmacoeconomics - Open|February 22, 2018
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in CanadaGraeme Ball, Feng Xie, Jean-Eric Tarride
Journal of Medical Economics|September 16, 2025
Navigating the economic value of treatment sequencing in large B-cell lymphoma: insights into optimizing value and patient outcomes of CAR T-cell and other available therapies in BrazilSamir Nabhan, Bradley Kievit, Rob Blissett, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in CanadaGraeme Ball, Christopher Lemieux, David Cameron, et al.
Nature|December 24, 2013
RecA bundles mediate homology pairing between distant sisters during DNA break repairChristian Lesterlin, Graeme Ball, Lothar Schermelleh, et al.
Pharmacoeconomics - Open|April 24, 2021
Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in OncologyGraeme Ball, Mitch Levine, Lehana Thabane, et al.
Mechanisms of Ageing and Development|December 18, 2019
Semi-automated quantitation of mitophagy in cells and tissuesLambert Montava-Garriga, François Singh, Graeme Ball, et al.
Methods in Enzymology|January 24, 2012
A cell biologist's guide to high resolution imagingGraeme Ball, Richard M Parton, Russell S Hamilton, et al.
Current Oncology (Toronto, Ont.)|October 27, 2022
Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and AustraliaGraeme Ball, Mitchell A H Levine, Lehana Thabane, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
Health Technology Reassessment: Addressing Uncertainty in Economic Evaluations of Oncology Drugs at Time of Reimbursement Using Long-Term Clinical Trial DataGraeme Ball, Mitchell A H Levine, Lehana Thabane, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Pharmacoeconomics|July 17, 2022
The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in CanadaChristopher Hillis, Colin Vicente, Graeme Ball
Pharmacoeconomics - Open|February 22, 2018
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in CanadaGraeme Ball, Feng Xie, Jean-Eric Tarride
Journal of Medical Economics|September 16, 2025
Navigating the economic value of treatment sequencing in large B-cell lymphoma: insights into optimizing value and patient outcomes of CAR T-cell and other available therapies in BrazilSamir Nabhan, Bradley Kievit, Rob Blissett, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in CanadaGraeme Ball, Christopher Lemieux, David Cameron, et al.
Nature|December 24, 2013
RecA bundles mediate homology pairing between distant sisters during DNA break repairChristian Lesterlin, Graeme Ball, Lothar Schermelleh, et al.
Pharmacoeconomics - Open|April 24, 2021
Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in OncologyGraeme Ball, Mitch Levine, Lehana Thabane, et al.
Mechanisms of Ageing and Development|December 18, 2019
Semi-automated quantitation of mitophagy in cells and tissuesLambert Montava-Garriga, François Singh, Graeme Ball, et al.
Methods in Enzymology|January 24, 2012
A cell biologist's guide to high resolution imagingGraeme Ball, Richard M Parton, Russell S Hamilton, et al.
Current Oncology (Toronto, Ont.)|October 27, 2022
Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and AustraliaGraeme Ball, Mitchell A H Levine, Lehana Thabane, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
Health Technology Reassessment: Addressing Uncertainty in Economic Evaluations of Oncology Drugs at Time of Reimbursement Using Long-Term Clinical Trial DataGraeme Ball, Mitchell A H Levine, Lehana Thabane, et al.
Pageof 5